Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat for pulmonary hypertension associated with idiopathic interstitial pneumonias
2010-024332-42Phase 2Terminated
- Sponsor
- Bayer
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Idiopathic Interstitial Pneumonia Associated Pulmonary Hypertension (IIP-PH) and idiopathic interstitial pneumonia (IIP) comparing Riociguat with Placebo (2 arms). Primary endpoint: Mean change in 6-minute walking distance from baseline to week 26. Started Mar 2014; status: terminated.
02
Drugs
riociguat
03
Conditions
Idiopathic Interstitial Pneumonia Associated Pulmonary Hypertension (IIP-PH)idiopathic interstitial pneumonia (IIP)
Beyond the preview
Go deeper on 2010-024332-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024332-42.